Market capitalization | $18.37m |
Enterprise Value | $1.71m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.12 |
P/S ratio (TTM) P/S ratio | 12.01 |
P/B ratio (TTM) P/B ratio | 1.05 |
Sales growth (TTM) Sales growth | -27.48% |
Turnover (TTM) Turnover | $1.53m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
3 Analysts have issued a Lumos Pharma Inc forecast:
3 Analysts have issued a Lumos Pharma Inc forecast:
Mar '24 | |
Current assets | 28 28 |
Fixed assets | 0.53 0.53 |
Total assets | 28 28 |
Mar '24 | |
Equity | 17 17 |
Debt capital | 11 11 |
Total capital | 28 28 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Head office | United States |
CEO | Richard Hawkins |
Employees | 33 |
Founded | 1999 |
Website | www.lumos-pharma.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.